

June 1, 2012  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director  
 President and Chief Executive Officer

SYMBIO ANNOUNCES DATA PRESENTATIONS AT 48<sup>th</sup> ANNUAL AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

TOKYO, Japan, June 1, 2012 – Symbio Pharmaceuticals Limited (JASDAQ: 4582) announced today that it will present data highlighting new study results related to bendamustine hydrochloride (TREAKISYM®) and oral rigosertib during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012.

Nine abstracts will be presented for bendamustine hydrochloride (TREAKISYM®), including results from the Japanese and Korean Lymphoma cooperative group-sponsored Phase 2 study for the treatment of refractory and relapsed aggressive non-Hodgkin's lymphoma in Japan. The results of this Phase 2 trial will be presented in an oral discussion by Dr. Michinori Ogura (Nagoya, Daini Red Cross Hospital) on June 2, 2012 from 12:00pm to 1:00pm in room E354a.

In partnership with Eisai Co., Ltd., Symbio received Japanese marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for the treatment of patients with refractory/relapsed low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. Symbio has also initiated Phase 2 trials for SyB L-0501 in frontline low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and refractory/relapsed multiple myeloma patients.

ASCO 2012 BENDAMUSTINE (TREAKISYM®) ABSTRACTS:

#	Abstract Number	Abstract Name
1	3	Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. <a href="http://abstract.asco.org/AbstView_114_95807.html">http://abstract.asco.org/AbstView_114_95807.html</a> Plenary session: Sunday June 3, 1:00pm to 4:00pm in N Hall B1
2	6515	Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. <a href="http://abstract.asco.org/AbstView_114_98278.html">http://abstract.asco.org/AbstView_114_98278.html</a> Poster discussion session: June 1, 1:00pm to 5:00pm in S405 Discussion time: Friday June 1, 4:30pm to 5:30pm in S406
3	6553	Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL). <a href="http://abstract.asco.org/AbstView_114_90712.html">http://abstract.asco.org/AbstView_114_90712.html</a> Poster viewing: Monday June 4, 1:15pm to 5:15pm in S Hall A2
4	6566	Bendamustine retreatment of CLL in the outpatient setting. <a href="http://abstract.asco.org/AbstView_114_96159.html">http://abstract.asco.org/AbstView_114_96159.html</a> General poster session: Monday June 4, 1:15pm to 5:15pm in S

		Hall A2
5	7094	A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). <a href="http://abstract.asco.org/AbstView_114_96985.html">http://abstract.asco.org/AbstView_114_96985.html</a> Poster viewing: Saturday June 2, 1:15pm to 5:15pm in S Hall A2
6	8014	Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. <a href="http://abstract.asco.org/AbstView_114_93400.html">http://abstract.asco.org/AbstView_114_93400.html</a> Oral abstract session: Sunday June 3, 8:00am to 11:00am in E354a
7	8023	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ( <b>Symbio-Sponsored Study</b> ) <a href="http://abstract.asco.org/AbstView_114_96015.html">http://abstract.asco.org/AbstView_114_96015.html</a> Poster viewing: Saturday June 2, 8:00am to 12:00pm in E450b Poster discussion: Saturday June 2, 12:00pm to 1:00pm in E354a
8	8026	Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial. <a href="http://abstract.asco.org/AbstView_114_97842.html">http://abstract.asco.org/AbstView_114_97842.html</a> Poster discussion session: Saturday June 2, 8:00am to 12:00pm in E450b Discussion time: Saturday June 2, 12:00pm to 1:00pm in E354a
9	9547	Pharmacokinetics (PK) of bendamustine in pediatric patients with relapsed/refractory acute leukemia. <a href="http://abstract.asco.org/AbstView_114_97053.html">http://abstract.asco.org/AbstView_114_97053.html</a> Poster viewing: Sunday June 3, 8:00am to 12:00pm at S Hall A2

In addition to TREAKISYM-related abstracts, two abstracts on rigosertib trials, sponsored by Onconova Therapeutics, Inc. have been accepted for presentation.

In Japan, Symbio received clinical trial approval for a Phase 1 study of rigosertib in relapsed/refractory myelodysplastic syndrome (MDS) patients. Symbio is also planning to initiate a Phase I clinical trial for the treatment of frontline MDS using the oral form of rigosertib based on promising results generated in U.S. Phase 2 clinical trials.

#### ASCO 2012 RIGOSERTIB ABSTRACTS

#	Abstract Number	Abstract Name
1	3017	Phase I study of oral rigosertib in patients with advanced solid tumors. ( <b>Sponsored by Onconova, Symbio's partner</b> ) <a href="http://abstract.asco.org/AbstView_114_98060.html">http://abstract.asco.org/AbstView_114_98060.html</a> Poster discussion session: Saturday June 2, 1:15pm to 5:15pm in S405 Discussion time: Saturday June 2, 4:45pm to 5:45pm in S406
2	3081	A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes. ( <b>Sponsored by Onconova, Symbio's partner</b> )

	<a href="http://abstract.asco.org/AbstView_114_96744.html">http://abstract.asco.org/AbstView_114_96744.html</a> Poster viewing: Monday June 4, 8:00am to 12:00pm in S Hall A2
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Contact]

Hiroki Maekawa

Board Director, Corporate Officer, Chief Financial Officer

Tel: +081(0)3 5472 1125